activins and oxidopamine

activins has been researched along with oxidopamine in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (33.33)29.6817
2010's2 (66.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Amit, T; Bar-Am, O; Blumenfeld, Z; Kupershmidt, L; Youdim, MB1
Li, KM; Rentsch, P; Stayte, S; Vissel, B1
Morris, GP; Rentsch, P; Stayte, S; Vissel, B1

Other Studies

3 other study(ies) available for activins and oxidopamine

ArticleYear
The neuroprotective effect of Activin A and B: implication for neurodegenerative diseases.
    Journal of neurochemistry, 2007, Volume: 103, Issue:3

    Topics: Activins; Animals; Apoptosis; Apoptosis Regulatory Proteins; Brain; Cell Line, Tumor; Cell Survival; Culture Media, Serum-Free; Histones; Humans; Molsidomine; Nerve Degeneration; Neurodegenerative Diseases; Neurons; Neuroprotective Agents; Oxidative Stress; Oxidopamine; PC12 Cells; Poly(ADP-ribose) Polymerases; Rats; Transfection; Tyrosine 3-Monooxygenase

2007
Activin A protects midbrain neurons in the 6-hydroxydopamine mouse model of Parkinson's disease.
    PloS one, 2015, Volume: 10, Issue:4

    Topics: Activins; Animals; Cell Survival; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Plasma Membrane Transport Proteins; Dopaminergic Neurons; Gene Expression Regulation; Injections, Intraventricular; Male; Mice; Mice, Inbred C57BL; Neuroprotective Agents; Oxidopamine; Parkinson Disease, Secondary; Pars Compacta; Signal Transduction; Stereotaxic Techniques

2015
Time dependent degeneration of the nigrostriatal tract in mice with 6-OHDA lesioned medial forebrain bundle and the effect of activin A on L-Dopa induced dyskinesia.
    BMC neuroscience, 2019, Feb-13, Volume: 20, Issue:1

    Topics: Activins; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antiparkinson Agents; Disease Progression; Dyskinesia, Drug-Induced; Levodopa; Male; Medial Forebrain Bundle; Mice, Inbred C57BL; Neurodegenerative Diseases; Neurons; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorders; Random Allocation; Treatment Failure

2019